Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

May 31, 2006

Conditions

Proliferative Diabetic Retinopathy

Interventions

DRUG

Octreotide, 30 mg i.m. LAR formulation

Trial Locations (1)

Novartis, Basel